Clinical trials update from the European Society of Cardiology meeting 2014: PARADIGM-HF, CONFIRM-HF, SIGNIFY, atrial fibrillation, beta-blockers and heart failure, and vagal stimulation in heart failure

Andrew L Clark; Pierpaolo Pellicori

doi:10.1002/ehf2.12012

Clinical trials update from the European Society of Cardiology meeting 2014: PARADIGM-HF, CONFIRM-HF, SIGNIFY, atrial fibrillation, beta-blockers and heart failure, and vagal stimulation in heart failure

ESC Heart Fail. 2014 Dec;1(2):82-86. doi: 10.1002/ehf2.12012. Epub 2014 Nov 24.

Authors

Andrew L Clark¹, Pierpaolo Pellicori¹

Affiliation

¹ Hull York Medical School, Castle Hill Hospital, Castle Road, Cottinham, Kingston upon Hull, HU16 5JQ, UK.

PMID: 28834633
DOI: 10.1002/ehf2.12012

Abstract

This article provides an overview of trials relevant to the pathophysiology, prevention, and treatment of heart failure, presented at the European Society of Cardiology meeting held in Barcelona in autumn 2014. Trials reported here include PARADIGM-HF (LCZ696 versus enalapril in heart failure), CONFIRM-HF (treatment of iron deficiency in heart failure), and SIGNIFY (ivabradine in patients with stable coronary artery disease). In addition, we discuss recent developments in the treatment of atrial fibrillation and the lack of benefit with the use of beta-blockers in these patients. Finally, the article describes recent advances in the use of vagal stimulation in patients with heart failure. © 2014 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

Keywords: European Society of Cardiology 2014; Heart failure; Randomized controlled trials.

Publication types

Review